Impact of Comorbidities and Age on Cause‐Specific Mortality in Postmenopausal Patients with Breast Cancer

AbstractBackground.The aim was to study the impact of comorbidities and age on breast cancer mortality, taking into account competing causes of death.Subjects, Materials, and Methods.Cohort analysis of Dutch and Belgian patients with postmenopausal, early hormone receptor‐positive breast cancer included in the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial between 2001 and 2006. This is a randomized controlled trial of patients who had completed local treatment with curative intent and were randomized to receive exemestane for 5 years, or sequential treatment of tamoxifen followed by exemestane for a duration of 5 years. Patients were categorized by number of comorbidities (no comorbidities, 1–2 comorbidities, and>2 comorbidities) and age (

Source: The Oncologist - July 16, 2019 Category: Cancer & Oncology Authors: Marloes G.M. Derks, Cornelis J.H. van de Velde, Daniele Giardiello, Caroline Seynaeve, Hein Putter, Johan W.R. Nortier, Luc Y. Dirix, Esther Bastiaannet, Johanneke E.A. Portielȷe, Gerrit-Jan Liefers Tags: Geriatric Oncology Source Type: research